Recombinant Bovine IL-4

Catalog Number: 2469-BL

DESCRIPTION

Source	*E. coli*-derived His25-Cys135, with an N-terminal Met Accession # P30367.2
N-terminal Sequence Analysis	Met
Predicted Molecular Mass	12.7 kDa

SPECIFICATIONS

Activity	Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. Kitamura, T. *et al.* (1989) J. Cell Physiol. **140**:323. The ED_{50} for this effect is typically 0.05-0.3 ng/mL.
Endotoxin Level	<1.0 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Interleukin-4 (IL-4), also known as B cell-stimulatory factor-1, is a monomeric, approximately 13 kDa-18 kDa Th2 cytokine that shows pleiotropic effects during immune responses (1-3). It is a glycosylated polypeptide that contains three intrachain disulfide bridges and adopts a bundled four α-helix structure (4). Bovine IL-4 is synthesized with a 24 amino acid (aa) signal sequence. Alternate splicing generates two additional isoforms with internal deletions (5). Mature bovine IL-4 shares 60%, 91%, 93%, 78%, 55%, 39%, and 41% aa sequence identity with equine, goat, ovine, porcine, human, mouse, and rat IL-4, respectively. IL-4 exerts its effects through two receptor complexes (6, 7). The type I receptor, which is expressed on hematopoietic cells, is a heterodimer of the ligand binding IL-4 Rα and the common γ chain (a shared subunit of the receptors for IL-2, -7, -9, -15, and -21). The type II receptor on nonhematopoietic cells consists of IL-4 Rα and IL-13 Rα1. The type II receptor also transduces IL-13 mediated signals. IL-4 is primarily expressed by Th2-biased $CD4^+$ T cells, mast cells, basophils, and eosinophils (1, 2). It promotes cell proliferation, survival, and immunoglobulin class switch to IgE in B cells, acquisition of the Th2 phenotype by naïve $CD4^+$ T cells, priming and chemotaxis of mast cells, eosinophils, and basophils, and the proliferation and activation of epithelial cells (8-11). IL-4 plays a dominant role in the development of allergic inflammation and asthma (10, 12).

References:

1. Benczik, M. and S.L. Gaffen (2004) Immunol. Invest. **33**:109.
2. Chomarat, P. and J. Banchereau (1998) Int. Rev. Immunol. **17**:1.
3. Heussler, V.T. *et al.* (1992) Gene **114**:273.
4. Redfield, C. *et al.* (1991) Biochemistry **30**:11029.
5. Waldvogel, A.S. *et al.* (2004) Vet. Immunol. Immunopathol. **97**:53.
6. Mueller, T.D. *et al.* (2002) Biochim. Biophys. Acta **1592**:237.
7. Nelms, K. *et al.* (1999) Annu. Rev. Immunol. **17**:701.
8. Paludan, S.R. (1998) Scand. J. Immunol. **48**:459.
9. Corthay, A. (2006) Scand. J. Immunol. **64**:93.
10. Ryan, J.J. *et al.* (2007) Crit. Rev. Immunol. **27**:15.
11. Grone, A. (2002) Vet. Immunol. Immunopathol. **88**:1.
12. Rosenberg, H.F. *et al.* (2007) J. Allergy Clin. Immunol. **119**:1303.